-
Je něco špatně v tomto záznamu ?
A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors
K. Němejcová, MK. Bártů, R. Michálková, J. Drozenová, P. Fabian, O. Fadare, J. Hausnerová, J. Laco, R. Matěj, G. Méhes, N. Singh, S. Stolnicu, P. Škapa, M. Švajdler, I. Stružinská, D. Cibula, R. Kocian, SF. Lax, WG. McCluggage, P. Dundr
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
BioMedCentral
od 2006-12-01
BioMedCentral Open Access
od 2006
Directory of Open Access Journals
od 2006
Free Medical Journals
od 2006
PubMed Central
od 2006
Europe PubMed Central
od 2006
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
Springer Nature OA/Free Journals
od 2006-12-01
- MeSH
- endometroidní karcinom * patologie MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- mucinózní adenokarcinom * diagnóza patologie MeSH
- nádorové biomarkery analýza MeSH
- nádory vaječníků * patologie MeSH
- peritoneální nádory * MeSH
- prekancerózy * MeSH
- serózní cystadenokarcinom * metabolismus MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: IMP2 and IMP3 are mRNA binding proteins involved in carcinogenesis. We examined a large cohort of ovarian tumors with the aim to assess the value of IMP2 and IMP3 for differential diagnosis, and to assess their prognostic significance. METHODS: Immunohistochemical analyses with antibodies against IMP2 and IMP3 were performed on 554 primary ovarian tumors including 114 high grade serous carcinomas, 100 low grade serous carcinomas, 124 clear cell carcinomas, 54 endometrioid carcinomas, 34 mucinous carcinomas, 75 mucinous borderline tumors, and 41 serous borderline tumors (micropapillary variant). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test. RESULTS: We found IMP2 expression (in more than 5% of tumor cells) in nearly all cases of all tumor types, so the prognostic meaning could not be analyzed. The positive IMP3 expression (in more than 5% of tumor cells) was most common in mucinous carcinomas (82%) and mucinous borderline tumors (81%), followed by high grade serous (67%) and clear cell carcinomas (67%). The expression was less frequent in endometrioid carcinomas (39%), low grade serous carcinomas (23%), and micropapillary variant of serous borderline tumors (20%). Prognostic significance of IMP3 could be evaluated only in low grade serous carcinomas in the case of relapse-free survival, where negative cases showed better RFS (p = 0.033). CONCLUSION: Concerning differential diagnosis our results imply that despite the differences in expression in the different ovarian tumor types, the practical value for diagnostic purposes is limited. Contrary to other solid tumors, we did not find prognostic significance of IMP3 in ovarian cancer, with the exception of RFS in low grade serous carcinomas. However, the high expression of IMP2 and IMP3 could be of predictive value in ovarian carcinomas since IMP proteins are potential therapeutical targets.
Department of Oncological Pathology Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Pathology Belfast Health and Social Care Trust Belfast UK
Department of Pathology Faculty of Medicine University of Debrecen Debrecen 4032 Hungary
Department of Pathology University of California San Diego San Diego CA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004240
- 003
- CZ-PrNML
- 005
- 20230425141228.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13000-023-01300-4 $2 doi
- 035 __
- $a (PubMed)36740684
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic. Kristyna.Nemejcova@vfn.cz $1 https://orcid.org/0000000193409320 $7 xx0233214
- 245 12
- $a A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors / $c K. Němejcová, MK. Bártů, R. Michálková, J. Drozenová, P. Fabian, O. Fadare, J. Hausnerová, J. Laco, R. Matěj, G. Méhes, N. Singh, S. Stolnicu, P. Škapa, M. Švajdler, I. Stružinská, D. Cibula, R. Kocian, SF. Lax, WG. McCluggage, P. Dundr
- 520 9_
- $a BACKGROUND: IMP2 and IMP3 are mRNA binding proteins involved in carcinogenesis. We examined a large cohort of ovarian tumors with the aim to assess the value of IMP2 and IMP3 for differential diagnosis, and to assess their prognostic significance. METHODS: Immunohistochemical analyses with antibodies against IMP2 and IMP3 were performed on 554 primary ovarian tumors including 114 high grade serous carcinomas, 100 low grade serous carcinomas, 124 clear cell carcinomas, 54 endometrioid carcinomas, 34 mucinous carcinomas, 75 mucinous borderline tumors, and 41 serous borderline tumors (micropapillary variant). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test. RESULTS: We found IMP2 expression (in more than 5% of tumor cells) in nearly all cases of all tumor types, so the prognostic meaning could not be analyzed. The positive IMP3 expression (in more than 5% of tumor cells) was most common in mucinous carcinomas (82%) and mucinous borderline tumors (81%), followed by high grade serous (67%) and clear cell carcinomas (67%). The expression was less frequent in endometrioid carcinomas (39%), low grade serous carcinomas (23%), and micropapillary variant of serous borderline tumors (20%). Prognostic significance of IMP3 could be evaluated only in low grade serous carcinomas in the case of relapse-free survival, where negative cases showed better RFS (p = 0.033). CONCLUSION: Concerning differential diagnosis our results imply that despite the differences in expression in the different ovarian tumor types, the practical value for diagnostic purposes is limited. Contrary to other solid tumors, we did not find prognostic significance of IMP3 in ovarian cancer, with the exception of RFS in low grade serous carcinomas. However, the high expression of IMP2 and IMP3 could be of predictive value in ovarian carcinomas since IMP proteins are potential therapeutical targets.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mucinózní adenokarcinom $x diagnóza $x patologie $7 D002288
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 650 12
- $a endometroidní karcinom $x patologie $7 D018269
- 650 12
- $a serózní cystadenokarcinom $x metabolismus $7 D018284
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 12
- $a nádory vaječníků $x patologie $7 D010051
- 650 12
- $a peritoneální nádory $7 D010534
- 650 12
- $a prekancerózy $7 D011230
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bártů, Michaela Kendall $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Michálková, Romana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Drozenová, Jana $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic
- 700 1_
- $a Fabian, Pavel $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Fadare, Oluwole $u Department of Pathology, University of California San Diego, San Diego, CA, USA
- 700 1_
- $a Hausnerová, Jitka $u Department of Pathology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Laco, Jan $u The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Matěj, Radoslav $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic
- 700 1_
- $a Méhes, Gábor $u Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, 4032, Hungary
- 700 1_
- $a Singh, Naveena $u Department of Cellular Pathology, Barts Health NHS Trust, and Blizard Institute of Core Pathology, Queen Mary University of London, London, UK
- 700 1_
- $a Stolnicu, Simona $u Department of Pathology, University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, Târgu Mureș, Romania
- 700 1_
- $a Škapa, Petr $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Švajdler, Marián $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Stružinská, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Cibula, David $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000, Prague, Czech Republic
- 700 1_
- $a Kocian, Roman $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000, Prague, Czech Republic
- 700 1_
- $a Lax, Sigurd F $u Department of Pathology, Hospital Graz II, Graz, Austria, and Johannes Kepler University Linz, Linz, Austria
- 700 1_
- $a McCluggage, W Glenn $u Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK
- 700 1_
- $a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 773 0_
- $w MED00165474 $t Diagnostic pathology $x 1746-1596 $g Roč. 18, č. 1 (2023), s. 15
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36740684 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141225 $b ABA008
- 999 __
- $a ok $b bmc $g 1924731 $s 1190449
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 18 $c 1 $d 15 $e 20230206 $i 1746-1596 $m Diagnostic pathology $n Diagn Pathol $x MED00165474
- LZP __
- $a Pubmed-20230418
